Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stakeholder-informed environmental-economic tradeoffs at the farm and forest scale.

Journal of environmental management·2026

Same author

Excitonic absorption and defect-related emission in three-dimensional MoS<sub>2</sub> pyramids.

Nanoscale·2021

Same author

Effective discrimination of gas-phase peptide conformers using TIMS-ECD-ToF MS/MS.

Analytical methods : advancing methods and applications·2021

Same author

Estimating neuronal conductance model parameters using dynamic action potential clamp.

Journal of neuroscience methods·2019

Same author

Diagnosis and treatment of necrotising otitis externa and diabetic foot osteomyelitis - similarities and differences.

The Journal of laryngology and otology·2018

Same author

The incidence of hyperthermia during cochlear implant surgery in children.

The Journal of laryngology and otology·2017

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Abelson virus-transformed lymphocytes: null cells that modulate H-2.

D M Pratt, J Strominger, R Parkman

|November 1, 1977

Summary

A-MuLV-transformed lymphoid cells exhibit altered H-2 antigen expression. These cells modulate H-2 levels higher in vivo and lower in vitro, impacting tumor formation and immune recognition.

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes

Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes

Published on: February 11, 2015

Related Experiment Videos

Last Updated: Jun 25, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes

Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes

Published on: February 11, 2015

Area of Science:

Immunology
Virology
Cell Biology

Background:

Murine Leukemia Virus (MuLV) transformation induces changes in lymphoid cell properties.
Understanding the behavior of transformed cells is crucial for cancer research.

Purpose of the Study:

To investigate the expression and modulation of H-2 histocompatibility antigens in A-MuLV-transformed lymphoid cells.
To determine the impact of H-2 modulation on tumor formation in vivo.

Main Methods:

Characterization of A-MuLV-transformed Balb/c mouse lymphoid cells.
Assessment of cell-associated and secreted immunoglobulin (Ig).
Analysis of H-2D, H-2K, H-2I, and theta-antigen expression.
Tumorigenicity assays in (Balb/c X C57B1/6)F1 mice.
In vitro and in vivo H-2 antigen modulation studies using anti-H-2Dd sera and cloning.

Main Results:

Transformed cells displayed null lymphocyte characteristics, lacking significant Ig secretion or cell-associated Ig.
Cells expressed H-2D and H-2K but not H-2I or theta-antigen, possessing Fc receptors.
Tumorigenicity was observed, with in vivo passaged cells showing increased H-2Dd expression compared to in vitro cultured cells.
In vitro culture led to progressive loss of H-2Dd, while cloning demonstrated H-2 modulation capabilities.
Tumorigenic clones with low H-2Dd expression remained tumorigenic even after antibody treatment, with tumors exhibiting higher H-2Dd levels.

Conclusions:

A-MuLV-transformed lymphocytes exhibit significant H-2 antigen modulation.
H-2 antigen levels are upregulated in vivo during tumor formation.
H-2 antigen levels are downregulated in vitro, suggesting distinct regulatory mechanisms.